Jennifer A Rivard
Examiner (ID: 3971, Phone: (571)272-2609 , Office: P/2911 )
Most Active Art Unit | 2911 |
Art Unit(s) | 2901, 2911, 2900 |
Total Applications | 6935 |
Issued Applications | 6877 |
Pending Applications | 7 |
Abandoned Applications | 50 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18939677
[patent_doc_number] => 20240034816
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERING
[patent_app_type] => utility
[patent_app_number] => 18/469947
[patent_app_country] => US
[patent_app_date] => 2023-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53529
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18469947
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/469947 | NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERING | Sep 18, 2023 | Pending |
Array
(
[id] => 18725875
[patent_doc_number] => 20230340105
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => NOVEL ANTIGEN BINDING MOLECULE FORMATS
[patent_app_type] => utility
[patent_app_number] => 18/318871
[patent_app_country] => US
[patent_app_date] => 2023-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47652
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18318871
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/318871 | NOVEL ANTIGEN BINDING MOLECULE FORMATS | May 16, 2023 | Pending |
Array
(
[id] => 18725874
[patent_doc_number] => 20230340104
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS
[patent_app_type] => utility
[patent_app_number] => 18/308338
[patent_app_country] => US
[patent_app_date] => 2023-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 135551
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18308338
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/308338 | IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS | Apr 26, 2023 | Pending |
Array
(
[id] => 18537555
[patent_doc_number] => 20230242653
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/164442
[patent_app_country] => US
[patent_app_date] => 2023-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67911
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 147
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164442
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/164442 | Agonistic anti-IL-2R antibodies and methods of use | Feb 2, 2023 | Issued |
Array
(
[id] => 18420171
[patent_doc_number] => 20230174632
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => COMBINATIONS FOR ALLERGY THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/980397
[patent_app_country] => US
[patent_app_date] => 2022-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14226
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17980397
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/980397 | COMBINATIONS FOR ALLERGY THERAPY | Nov 2, 2022 | Pending |
Array
(
[id] => 18391416
[patent_doc_number] => 20230159634
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => ANTIBODIES THAT BIND HUMAN CANNABINOID 1 (CB1) RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 17/877432
[patent_app_country] => US
[patent_app_date] => 2022-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43366
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17877432
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/877432 | ANTIBODIES THAT BIND HUMAN CANNABINOID 1 (CB1) RECEPTOR | Jul 28, 2022 | Pending |
Array
(
[id] => 18294260
[patent_doc_number] => 20230103946
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => THERAPEUTIC INTERFERON ALPHA 1 PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/813985
[patent_app_country] => US
[patent_app_date] => 2022-07-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 75881
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17813985
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/813985 | THERAPEUTIC INTERFERON ALPHA 1 PROTEINS | Jul 20, 2022 | Pending |
Array
(
[id] => 18036258
[patent_doc_number] => 20220380473
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => ANTI-GAL3 ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/813578
[patent_app_country] => US
[patent_app_date] => 2022-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48001
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17813578
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/813578 | ANTI-GAL3 ANTIBODIES AND USES THEREOF | Jul 18, 2022 | Pending |
Array
(
[id] => 17982605
[patent_doc_number] => 20220348641
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => PROCESS FOR OBTAINING ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/858112
[patent_app_country] => US
[patent_app_date] => 2022-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12564
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17858112
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/858112 | PROCESS FOR OBTAINING ANTIBODIES | Jul 5, 2022 | Pending |
Array
(
[id] => 18065535
[patent_doc_number] => 20220396622
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-15
[patent_title] => FC VARIANTS WITH REDUCED EFFECTOR FUNCTION
[patent_app_type] => utility
[patent_app_number] => 17/848808
[patent_app_country] => US
[patent_app_date] => 2022-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8392
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17848808
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/848808 | FC VARIANTS WITH REDUCED EFFECTOR FUNCTION | Jun 23, 2022 | Pending |
Array
(
[id] => 18980169
[patent_doc_number] => 11905329
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-20
[patent_title] => Anti-PD-1 antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/834237
[patent_app_country] => US
[patent_app_date] => 2022-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 45420
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17834237
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/834237 | Anti-PD-1 antibodies and uses thereof | Jun 6, 2022 | Issued |
Array
(
[id] => 18519279
[patent_doc_number] => 11709167
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-25
[patent_title] => Generation of human allergen- and helminth-specific IgE monoclonal antibodies for diagnostic and therapeutic use
[patent_app_type] => utility
[patent_app_number] => 17/826108
[patent_app_country] => US
[patent_app_date] => 2022-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 8
[patent_no_of_words] => 29656
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17826108
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/826108 | Generation of human allergen- and helminth-specific IgE monoclonal antibodies for diagnostic and therapeutic use | May 25, 2022 | Issued |
Array
(
[id] => 17865461
[patent_doc_number] => 20220288196
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => METHODS OF ORAL IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 17/752639
[patent_app_country] => US
[patent_app_date] => 2022-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40628
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17752639
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/752639 | METHODS OF ORAL IMMUNOTHERAPY | May 23, 2022 | Pending |
Array
(
[id] => 18468858
[patent_doc_number] => 20230203141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => METHODS OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/736859
[patent_app_country] => US
[patent_app_date] => 2022-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49586
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736859
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/736859 | METHODS OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES | May 3, 2022 | Pending |
Array
(
[id] => 18020618
[patent_doc_number] => 20220372117
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => ANTI-ALLERGEN ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/714507
[patent_app_country] => US
[patent_app_date] => 2022-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22654
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17714507
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/714507 | ANTI-ALLERGEN ANTIBODIES | Apr 5, 2022 | Pending |
Array
(
[id] => 18732566
[patent_doc_number] => 11801286
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-31
[patent_title] => Recombinant intravenous immunoglobulin (RIVIG) compositions and methods for their production and use
[patent_app_type] => utility
[patent_app_number] => 17/707243
[patent_app_country] => US
[patent_app_date] => 2022-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 12596
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707243
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/707243 | Recombinant intravenous immunoglobulin (RIVIG) compositions and methods for their production and use | Mar 28, 2022 | Issued |
Array
(
[id] => 17719123
[patent_doc_number] => 20220211842
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => Methods and Devices for the Treatment of Food Allergies
[patent_app_type] => utility
[patent_app_number] => 17/697467
[patent_app_country] => US
[patent_app_date] => 2022-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16960
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -164
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17697467
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/697467 | Methods and Devices for the Treatment of Food Allergies | Mar 16, 2022 | Pending |
Array
(
[id] => 17850596
[patent_doc_number] => 20220280637
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/672571
[patent_app_country] => US
[patent_app_date] => 2022-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19776
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17672571
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/672571 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | Feb 14, 2022 | Pending |
Array
(
[id] => 18518526
[patent_doc_number] => 11708407
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-25
[patent_title] => Antigen binding molecule formats
[patent_app_type] => utility
[patent_app_number] => 17/666116
[patent_app_country] => US
[patent_app_date] => 2022-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 43
[patent_figures_cnt] => 48
[patent_no_of_words] => 45802
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 211
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17666116
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/666116 | Antigen binding molecule formats | Feb 6, 2022 | Issued |
Array
(
[id] => 17958664
[patent_doc_number] => 20220339244
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => METHODS OF TREATING KAWASAKI DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/648242
[patent_app_country] => US
[patent_app_date] => 2022-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16375
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17648242
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/648242 | METHODS OF TREATING KAWASAKI DISEASE | Jan 17, 2022 | Pending |